MedTrace Logo

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

NCT04409288 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2024-01-05

No results posted yet for this study

Summary

This is a prospective, open-label, randomized, controlled, cross-over trial assessing patient preference for apalutamide versus enzalutamide in 146 male patients with recurrent or metastatic hormone-sensitive prostate cancer. The primary objective is to investigate whether there is any difference in patient preference between apalutamide and enzalutamide in patients with recurrent or metastatic hormone-sensitive prostate cancer.

Conditions

Interventions

DRUG

Apalutamide

Androgen receptor inhibitor.

DRUG

Enzalutamide

Androgern receptor inhibitor

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Chi Fai NG, MD · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2023-10-16
Completion
2023-10-16
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04409288 on ClinicalTrials.gov